Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy

Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy

Rectal cancer accounts for 30–40% of colorectal cancer (CRC) and is the most common cancer-related death worldwide. The preoperative neoadjuvant chemoradiotherapy (neoCRT) regimen is the main therapeutic strategy for patients with locally advanced rectal cancer (LARC) to control tumor growth and red...

Full description

Bibliographic Details
Main Authors: Kevin Chih-Yang Huang, Shu-Fen Chiang, Pei-Chen Yang, Tao-Wei Ke, Tsung-Wei Chen, Ching-Han Hu, Yi-Wen Huang, Hsin-Yu Chang, William Tzu-Liang Chen, K. S. Clifford Chao
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
locally advanced rectal cancer
neoadjuvant chemoradiotherapy
topoisomerase I inhibitor
lipotecan
anticancer immunity
Online Access:https://www.mdpi.com/2072-6694/13/6/1218

Internet

https://www.mdpi.com/2072-6694/13/6/1218

Similar Items